FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

				VVd3	sington	, 0.0.	20040				OMB AF	PROVAL	
Check this box Section 16. For obligations may Instruction 1(b)	continue. See	to S	Filed pu	IT OF CHANGES IN BENEFICIAL OWNERSHIP									
1. Name and Address of Reporting Person [*] Jones Elaine V (Last) (First) (Middle) C/O TARGACEPT, INC. 200 EAST FIRST STREET, SUITE 300				2. Issuer Name and <u>TARGACEPT</u> 3. Date of Earliest Tr 05/29/2007	Ticker c ` <mark>INC</mark>	or Trac [TF	ling Symbol		5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner Officer (give title Other (specify below) below)				
(Street) WINSTON- SALEM (City)	NC 27101			4. If Amendment, Date of Original Filed (Month/Day/Year)						6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person			
		Table I -	Non-Derivati	ve Securities A	Acqui	red,	Disposed	of, or	Benefic	ially Owned			
1. Title of Security (Instr. 3) 2. Trans Date		2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr.		
					Code	v	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)		4)	
Common Stock			05/29/2007		М		5,333	A	\$0.075	1,516,216	I	By EuclidSR Partners, L.P.	
Common Stock										371,945	I	By EuclidSR Biotechnology Partners, L.P.	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

	(e.g., puts, cans, warrants, options, convertible securities)														
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (Right to Buy)	\$0.075	05/29/2007		x			4,333	(3)	08/07/2012	Common Stock	4,333	\$0	0	I	By EuclidSR Partners L.P. ⁽¹⁾
Stock Option (Right to Buy)	\$0.075	05/29/2007		x			1,000	06/11/2004	06/10/2013	Common Stock	1,000	\$0	0	Ι	By EuclidSR Partners L.P. ⁽¹⁾

Explanation of Responses:

1. The reporting person is a general partner of EuclidSR Associates, L.P., the general partner of EuclidSR Partners, L.P. The reporting person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein.

2. The reporting person is a general partner of EuclidSR Biotechnology Associates, L.P., the general partner of EuclidSR Biotechnology Partners, L.P. The reporting person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein.

3. This stock option became exercisable for (1) 3,333 shares of common stock on August 8, 2002 and (2) the remaining 1,000 shares of common stock on May 15, 2003.

Remarks:

/s/ Peter A. Zorn, Attorney-in-05/31/2007

** Signature of Reporting Person Date

Fact

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.